Skip to Content

Welcome to our new website!

Menu

Treadwell Corporation

Treadwell Corporation is an affiliate company of the Union River Center for Innovation, taking part in the incubator program in a remote setting. Founded in 2005 by Richard Hand, PT, Treadwell Corporation first aimed to create and produce a product to combat Sedentary Death Syndrome. The result was a treadling product that allows the patient to tread their feet while sitting to increase blood flow without raising their pulse or blood pressure. Initial commercialization of the product appeared in 2009; the same year Gerald Collins, MBA joined the team. Since then, a patent for the product was granted in 2011, and a study regarding Peripheral Artery Disease funded by the National Institute of Health commenced in 2018. Though the company was originally formed on the idea of selling a product, it has transformed into a system concept over the years. 

Jerry Collins of Treadwell Corporation demonstrates their patented system.

Treadwell Corporation is a member of Union River Center for Innovation’s affiliate company program, where they are able to take part in the Center’s resources via a remote setting. Since joining URCI’s program, Treadwell Corporation has been grateful to utilize the Center’s abundant resources, including a working space, availability of conference space, and the ample interaction with other entrepreneurs at the Center. Additionally, the Center was able to connect Treadwell Industries with the Foster Center for Innovation at the University of Maine, as well as assisting in pursuing support from the Maine Technology Institute. 

Treadwell Corporation is planning for a busy year ahead, with multiple business and research goals on their horizon. To gain a more broad understanding of the needs of their target market, the company would like to survey nursing home administrators to learn what their largest areas of need are. To further their business operations, Treadwell also plans to conduct additional device prototyping, update their existing website, and expand their protocol library. In the coming year, Treadwell Corporation also hopes to submit phase II of their STTR grant application, which should occur following receipt of successful results of the study’s first phase, which is currently analyzing the benefits associated with the Treadwell System for Peripheral Artery Disease patients. Also on the company’s agenda for 2020 is the resubmission of the first phase of their SBIR grant application analyzing the benefits of their patented system for Falls/Gait patients.  2020 also brings the potential for new funding and grant opportunities, like the potential to study the benefits of utilizing the Treadwell System for stroke patients. 

To learn more about Treadwell Corporation, please visit their website at https://www.treadwellness.com/.